ITLN1 and obesity disorder: Decreased omentin levels have been observed in obesity, insulin resistance, and type 2 diabetes, as well as in cardiovascular diseases such as atherosclerosis and other inflammatory diseases, particularly inflammatory bowel diseases [101,102,103].